Illinois 2025-2026 Regular Session

Illinois House Bill HB5116

Introduced
2/5/26  
Refer
2/10/26  
Refer
3/18/26  

Caption

CONTROLLED SUB-PMP DATA

Impact

If enacted, HB5116 would significantly affect state healthcare laws, particularly those related to the prescription and management of controlled substances. It seeks to centralize data collection regarding prescriptions, thus allowing for real-time monitoring of prescription practices. This change would likely lead to more informed prescribing decisions, potentially lowering the risks associated with prescription drug misuse and overdose within the community. The implications may also extend to training requirements for healthcare providers regarding the use of this data system.

Summary

House Bill 5116 aims to enhance the regulation and oversight of controlled substances through the implementation of a comprehensive Prescription Monitoring Program (PMP) data system. This bill emphasizes the importance of data management in combating prescription drug abuse and ensuring safe prescribing practices among healthcare providers. The proposed system is designed to track prescription patterns accurately and provide this information to authorized healthcare professionals to facilitate better drug utilization and patient safety.

Contention

There has been some contention surrounding HB5116, particularly concerning the data privacy and the administrative burden it may impose on healthcare providers. Critics argue that while the intent to manage prescription data better is commendable, there is a risk of overreach that could infringe on patient privacy rights. Additionally, providers may express concern about the potential complexity of complying with new monitoring protocols. Proponents of the bill, on the other hand, assert that the benefits of reducing prescription drug abuse far outweigh these risks and that appropriate measures can be taken to safeguard patient data.

Discussion

In legislative discussions, several stakeholders including healthcare professionals, pharmacists, and patient advocacy groups voiced their opinions on the bill. Advocates for the bill emphasized the necessity of addressing the opioid crisis and improving safety for patients receiving prescriptions. In contrast, those against it highlighted the need for careful consideration of the impact on provider workflows and patient confidentiality. The dialogue surrounding HB5116 reflects a broad consensus on the need for a better system to manage prescriptions, while still recognizing the importance of protecting individual rights.

Companion Bills

No companion bills found.

Previously Filed As

IL SB3521

CONTROLLED SUB-PMP DATA

IL SB4197

CONTROLLED SUB-PMP-INTERSTATE

IL SB3191

CONTROLLED SUBSTANCES-FENTANYL

IL SB3221

CONTROLLED SUB-XYLAZINE

IL HB4834

CONTROLLED SUB-TESTOSTERONE

IL SB3323

CONTROLLED SUB-TESTOSTERONE

IL HB1811

CONTROLLED SUB-PMP-INTERSTATE

IL HB5595

ISP-SEPARATE JUVENILE DATABASE

IL SB1773

CONTROLLED SUB-FENTANYL

IL HB2874

CONTROLLED SUB-EPHEDRINE

Similar Bills

No similar bills found.